Ocugen, Inc. - Common Stock (NQ:OCGN)

1.065 +0.025 (+2.40%)

Delayed Quote Updated: 11:11 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗

September 16, 2026

Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive...

Via MarketBeat

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗

August 15, 2026

Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in...

Via MarketBeat

Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Gene therapy developer advances three Phase III programs toward 2028 regulatory filings.

Via The Motley Fool

Topics Earnings Retirement

Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗

August 06, 2026

Via Chartmill

Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗

May 05, 2026

Via Chartmill

Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗

March 04, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Demystifying Ocugen: Insights From 5 Analyst Reviews ↗

August 04, 2025

Via Benzinga

Ocugen Q2 Earnings Call Highlights ↗

August 07, 2026

Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT...

Via MarketBeat

Topics Earnings

Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗

July 10, 2026

Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis...

Via MarketBeat

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗

May 13, 2026

Investors can find much better opportunities.

Via The Motley Fool

A Peek at Ocugen's Future Earnings ↗

July 31, 2025

Via Benzinga

Top movers in Monday's after hours session ↗

May 04, 2026

Via Chartmill

OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data ↗

March 17, 2026

Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday.

Via Stocktwits

Keep an eye on the top gainers and losers in Wednesday's session. ↗

March 11, 2026

Via Chartmill

Top movers in Wednesday's session ↗

March 11, 2026

Via Chartmill

Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

Ocugen (OCGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Did OCGN Stock Rise Today? ↗

February 25, 2026

Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year.

Via Stocktwits

Ocugen Stock Is Surging Today: What's Driving The Action? ↗

January 16, 2026

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.

Via Benzinga

OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗

January 12, 2026

Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined.

Via Stocktwits

Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Ocugen (OCGN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗

November 05, 2025

Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases.

Via Chartmill

Forecasting The Future: 4 Analyst Projections For Ocugen ↗

September 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 17, 2025

Via Benzinga

Why Ocugen Stock Zoomed 12% Higher Today ↗

September 15, 2025

A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.

Via The Motley Fool

Ocugen Shares Are Trading Higher Monday: What's Going On? ↗

September 15, 2025

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Via Benzinga

Ocugen (OCGN) Q2 Revenue Jumps 20% ↗

August 01, 2025

Via The Motley Fool

Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows ↗

August 01, 2025

Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism.

Via Chartmill

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Earnings Scheduled For August 1, 2025 ↗

August 01, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.